Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Improvement of the Value of Orally Administered Cancer Drugs: Arm 1: Osimertinib for Advanced EGFR-positive NSCLC Patients: A Phase II Study

NCT05037331 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT05037331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05037331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Improvement of the Value of Orally Administered Cancer Drugs: Arm 1: Osimertinib for Advanced EGFR-positive NSCLC Patients: A Phase II Study
Lead sponsor
National University Hospital, Singapore
Phase
Observational
Overall status
Recruiting
Start date
July 22, 2021
Completion date
June 30, 2026
Enrollment
58 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr positive non-small cell lung cancer, non small cell lung cancer